Table 1 Clinicopathological parameters of patients with CD68, CD163, VEGF-A, or VEGF-C expression in patients with NSCLC
Category (n = 349) | CD68 | CD163 | CD163 + /CD68 + (M2 ratio) | VEGF-A | VEGF-C | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
High n (%) | Low n (%) | p | High n (%) | Low n (%) | p | High n (%) | Low n (%) | p | High n (%) | Low n (%) | p | High n (%) | Low n (%) | p | |
Total | 174 (49.9) | 175 (50.1) | Â | 174 (49.9) | 175 (50.1) | Â | 174 (49.9) | 175 (50.1) | Â | 174 (49.9) | 175 (50.1) | Â | 175 (50.1) | 174 (49.9) | Â |
Age | Â | Â | 0.816 | Â | Â | 0.183 | Â | Â | 0.816 | Â | Â | 0.418 | Â | Â | 0.583 |
  < 60 | 36 (20.7) | 39 (22.3) |  | 43 (24.7) | 32 (18.3) |  | 36 (20.7) | 39 (22.3) |  | 41 (23.6) | 34 (19.4) |  | 35 (20.0) | 40 (23.0) |  |
  ≥ 60 | 138 (79.3) | 136 (77.7) |  | 131 (75.3) | 143 (81.7) |  | 138 (79.3) | 136 (77.7) |  | 133 (76.4) | 141 (80.6) |  | 140 (80.0) | 134 (77.0) |  |
Sex | Â | Â | 1.000 | Â | Â | 0.587 | Â | Â | 0.017 | Â | Â | 0.314 | Â | Â | 0.001 |
 Male | 120 (69.0) | 121 (69.1) |  | 123 (70.7) | 118 (67.4) |  | 131 (75.3) | 110 (62.9) |  | 125 (71.8) | 116 (66.3) |  | 136 (77.7) | 105 (60.3) |  |
 Female | 54 (31.0) | 54 (30.9) |  | 51 (29.3) | 57 (32.6) |  | 43 (24.7) | 65 (37.1) |  | 49 (28.2) | 59 (33.7) |  | 39 (22.3) | 69 (39.7) |  |
Tumor type |  |  | 0.231 |  |  | 0.027 |  |  | 0.585 |  |  | 0.015 |  |  |  < 0.001 |
 SqCC | 74 (42.5) | 61 (34.9) |  | 79 (45.4) | 56 (32.0) |  | 72 (41.4) | 63 (36.0) |  | 80 (46.0) | 55 (31.4) |  | 89 (50.9) | 46 (26.4) |  |
 AD | 99 (56.9) | 111 (63.4) |  | 94 (54.0) | 116 (66.3) |  | 100 (57.5) | 110 (62.9) |  | 93 (53.4) | 117 (66.9) |  | 86 (49.1) | 124 (71.3) |  |
 ADSq | 1(0.6) | 3 (1.7) |  | 1 (0.6) | 3 (1.7) |  | 2 (1.1) | 2 (1.1) |  | 1 (0.6) | 3 (1.7) |  | 0 | 4 (2.3) |  |
Grade | Â | Â | 0.030 | Â | Â | 0.360 | Â | Â | 0.446 | Â | Â | 0.446 | Â | Â | 0.001 |
 Well | 51 (29.3) | 74 (42.3) |  | 56 (32.2) | 69 (39.4) |  | 68 (39.1) | 57 (32.6) |  | 58 (33.3) | 67 (38.3) |  | 47 (26.9) | 78 (44.8) |  |
 Moderate | 84 (48.3) | 74 (42.3) |  | 84 (48.3) | 74 (42.3) |  | 75 (43.1) | 83 (47.4) |  | 79 (45.4) | 79 (45.1) |  | 95 (54.2) | 63 (36.2) |  |
 Poor | 39 (22.4) | 27 (15.4) |  | 34 (19.5) | 32 (18.3) |  | 31 (17.8) | 35 (20.0) |  | 37 (21.3) | 29 (16.6) |  | 33 (18.9) | 33 (19.0) |  |
  pT stage |  |  | 0.417 |  |  | 1.000 |  |  | 1.000 |  |  | 0.891 |  |  | 0.891 |
 T1-2 | 148 (85.1) | 155 (88.6) |  | 151 (86.8) | 152 (86.9) |  | 151 (86.8) | 152 (86.9) |  | 152 (87.4) | 151 (86.3) |  | 151 (86.3) | 152 (87.4) |  |
 T3-4 | 26 (14.9) | 20 (11.4) |  | 23 (13.2) | 23 (13.1) |  | 23 (13.2) | 23 (13.1) |  | 22 (12.6) | 24 (13.7) |  | 24 (13.7) | 22 (12.6) |  |
pN stage | Â | Â | 0.580 | Â | Â | 0.750 | Â | Â | 0.533 | Â | Â | 0.580 | Â | Â | 0.208 |
 0 | 126 (72.4) | 121 (69.1) |  | 125 (71.8) | 122 (69.7) |  | 120 (69.0) | 127 (72.6) |  | 126 (72.4) | 121 (69.1) |  | 118 (67.4) | 129 (74.1) |  |
 1–3 | 48 (27.6) | 54 (30.9) |  | 49 (28.2) | 53 (30.3) |  | 54 (31.0) | 48 (27.4) |  | 48 (27.6) | 54 (30.9) |  | 57 (32.6) | 45 (25.9) |  |
Stage | Â | Â | 0.659 | Â | Â | 0.914 | Â | Â | 0.125 | Â | Â | 0.407 | Â | Â | 0.106 |
 I | 110 (63.2) | 108 (61.7) |  | 111 (63.8) | 107 (61.1) |  | 108 (62.1) | 110 (62.9) |  | 112 (64.4) | 106 (60.6) |  | 100 (57.1) | 118 (67.8) |  |
 II | 34 (19.5) | 38 (21.7) |  | 36 (20.7) | 36 (20.6) |  | 34 (19.5) | 38 (21.7) |  | 38 (21.8) | 34 (19.4) |  | 45 (25.7) | 27 (15.6) |  |
 III | 25 (14.4) | 27 (15.4) |  | 24 (13.8) | 28 (16.0) |  | 31 (17.8) | 21 (12.0) |  | 22 (12.6) | 30 (17.1) |  | 26 (14.9) | 26 (14.9) |  |
 IV | 5 (2.9) | 2 (1.2) |  | 3 (1.7) | 4 (2.3) |  | 1 (0.6) | 6 (3.4) |  | 2 (1.2) | 5 (2.9) |  | 4 (2.3) | 3 (1.7) |  |